Literature DB >> 10935506

Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.

P De Feudis1, S Vignati, C Rossi, T Mincioni, R Giavazzi, M D'Incalci, M Broggini.   

Abstract

The proapoptotic gene bax is one of the downstream effectors of p53. The p53 binding site in the bax promoter is less responsive to p53 than the one in the growth arrest mediating gene p21. We introduced the bax gene under the control of 13 copies of a strong p53 responsive element into two ovarian cancer cell lines. The clones expressing bax under the control of p53 obtained from the wild-type (wt) p53-expressing cell line A2780 were much more sensitive (500- to 1000-fold) to the anticancer agent taxol than the parent cell line, with a higher percentage of cells undergoing apoptosis after drug treatment that was clearly p53-dependent and bax-mediated. Xenografts established in nude mice from one selected clone (A2780/C3) were more responsive to taxol than the parental line and the apoptotic response of A2780/C3 tumors was also increased after treatment. Introduction of the same plasmid into the p53 null SKOV3 cell line did not alter the sensitivity to taxol or the induction of apoptosis. In conclusion, driving the p53 response (after taxol treatment) by activating the bax gene rather than the p21 gene results in induction of massive apoptosis, in vitro and in vivo, and greatly enhances sensitivity to the drug.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10935506      PMCID: PMC1507571          DOI: 10.1038/sj.neo.7900086

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  32 in total

1.  Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c.

Authors:  T Rossé; R Olivier; L Monney; M Rager; S Conus; I Fellay; B Jansen; C Borner
Journal:  Nature       Date:  1998-01-29       Impact factor: 49.962

2.  Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents.

Authors:  T Kobayashi; S Ruan; K Clodi; K O Kliche; H Shiku; M Andreeff; W Zhang
Journal:  Oncogene       Date:  1998-03-26       Impact factor: 9.867

3.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

4.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

Authors:  T Miyashita; J C Reed
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

5.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.

Authors:  Z N Oltvai; C L Milliman; S J Korsmeyer
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

6.  Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice.

Authors:  M I Nicoletti; V Lucchini; G Massazza; B J Abbott; M D'Incalci; R Giavazzi
Journal:  Ann Oncol       Date:  1993-02       Impact factor: 32.976

7.  Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.

Authors:  S Fan; M L Smith; D J Rivet; D Duba; Q Zhan; K W Kohn; A J Fornace; P M O'Connor
Journal:  Cancer Res       Date:  1995-04-15       Impact factor: 12.701

8.  Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.

Authors:  E Boven; B Winograd; D P Berger; M P Dumont; B J Braakhuis; O Fodstad; S Langdon; H H Fiebig
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

Review 9.  Paclitaxel (taxol)

Authors:  E K Rowinsky; R C Donehower
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

10.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

Authors:  J W Harper; G R Adami; N Wei; K Keyomarsi; S J Elledge
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

View more
  2 in total

1.  c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation.

Authors:  Tamara Lotan; Jonathan Hickson; Jeffrey Souris; Dezheng Huo; Jennifer Taylor; Terry Li; Kristen Otto; Seiko Diane Yamada; Kay Macleod; Carrie W Rinker-Schaeffer
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

2.  Anti-tumor activity of Eurycoma longifolia root extracts against K-562 cell line: in vitro and in vivo study.

Authors:  Omar Saeed Ali Al-Salahi; Dan Ji; Amin Malik Shah Abdul Majid; Chan Kit-Lam; Wan Zaidah Abdullah; Abdelhamid Zaki; Shah Kamal Khan Jamal Din; Narazah Mohd Yusoff; Aman Shah Abdul Majid
Journal:  PLoS One       Date:  2014-01-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.